Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• The endothelin A receptor (ET(A)R) pathway is overexpressed in ovarian carcinoma, promoting tumor progression, survival, and invasion.
• ET(A)R signaling drives tumor growth, neoangiogenesis, and metastasis in various cancers.

Purpose of the Study:

• To evaluate the efficacy of the selective ET(A)R antagonist ABT-627 (atrasentan) as a monotherapy and in combination with taxane for ovarian cancer.
• To investigate the molecular mechanisms underlying ABT-627's antitumor activity, including its effects on proliferation, angiogenesis, and apoptosis.

Main Methods:

• In vitro studies using ovarian carcinoma cell lines and primary cultures to assess ABT-627's effects on proliferation, VEGF secretion, and chemosensitization.
• In vivo studies using ovarian carcinoma xenograft models in mice to evaluate tumor growth inhibition, microvessel density, VEGF expression, and apoptosis.

Main Results:

• ABT-627 significantly inhibited ovarian carcinoma cell proliferation and vascular endothelial growth factor (VEGF) secretion.
• ET(A)R blockade sensitized ovarian cancer cells to paclitaxel-induced apoptosis.
• In vivo, ABT-627 treatment significantly reduced tumor growth, microvessel density, VEGF, and matrix metalloproteinase-2 expression, while increasing apoptosis.
• Combination therapy with ABT-627 and paclitaxel demonstrated additive antitumor, apoptotic, and antiangiogenic effects.

Conclusions:

• ABT-627 is a promising candidate for clinical testing in ovarian cancer, particularly in combination with taxane-based chemotherapy.
• Targeting the ET(A)R pathway represents a viable therapeutic strategy for ovarian carcinoma, offering both direct antitumor and antiangiogenic benefits.